Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARETTA
NCT03879577Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Nov 2019
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, trastuzumab in breast cancer, sponsored by University of Chicago. Started Nov 2019; status: active, not recruiting.
02
Drugs
docetaxeltrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03879577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879577.